Skip to NavigationSkip to content

Akari CEO resigns over allegations of spending company funds

Published on: 11/05/18

Akari has lost its second CEO in 12 months after David Horn Solomon was accused of misusing the company credit card for personal purchases, it has been revealed; he resigned following an investigation by Akari and an independent law firm.

The magnitude of this misspending has not been confirmed, but the company did note that it considered them to be immaterial to its operations.

Horn Solomon’s predecessor, Gur Roshwalb, also quit the company amid controversy last year, after he was found to have contravened Akari policy and had approved false claims concerning one of the Phase 2 trials for its drug Coversin.  

His vacated role will be filled on a temporary basis by COO and board member Clive Richardson until a full-time replacement can be found.

Horn Solomon had previously served as CEO of Zealand Pharma between 2008 and 2015, before joining Akari at the end of August 2017.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches